Last reviewed · How we verify
Clopidogrel first
At a glance
| Generic name | Clopidogrel first |
|---|---|
| Also known as | C-T |
| Sponsor | Ping-Yen Liu |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- SIMPLAAFY Clinical Trial (NA)
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) (PHASE3)
- Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) (PHASE3)
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (PHASE4)
- Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE (PHASE3)
- Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel first CI brief — competitive landscape report
- Clopidogrel first updates RSS · CI watch RSS
- Ping-Yen Liu portfolio CI